Oral Tazemetostat in Combination With Rituximab in R/R FL
Status:
Terminated
Trial end date:
2021-01-29
Target enrollment:
Participant gender:
Summary
The goal of this study is to examine the feasibility and efficacy of adding the EZH2
inhibitor, Tazemetostat to rituixmab, standard second line or beyond therapy as a means to
improve disease response.